Core Viewpoint - The Schall Law Firm is investigating claims against Septerna, Inc. for potential violations of securities laws related to misleading statements and failure to disclose critical information to investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Septerna issued false or misleading statements and failed to disclose relevant information to investors [2]. - On February 18, 2025, Septerna announced the discontinuation of its Phase 1 clinical trial for SEP-786 due to two severe adverse events related to elevated unconjugated bilirubin [2]. - Following this announcement, Septerna's shares experienced a significant decline of 46.99% on the same day [2]. Group 2: Legal Representation - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3]. - Shareholders who suffered losses are encouraged to contact the firm for a free discussion of their rights [3].
SEPN Investors Have Opportunity to Join Septerna, Inc. Fraud Investigation with the Schall Law Firm